Showing 3811-3820 of 5646 results for "".
- Claris Bio Advances Corneal Healing Product Candidate; Secures New Fundinghttps://modernod.com/news/claris-bio-developer-of-corneal-healing-product-candidate-names-new-investor/2482042/Claris Bio unveiled the company and its lead program with a total of $57 million invested. Claris, initially funded in 2020, is developing recombinant human variant hepatocyte growth factor, dHGF, to accelerate and improve the quality of corneal healing in patients with corneal eye dise
- Harrow Partners with Healthcare Market Access Technology Platforms to Support Launch of Vevyehttps://modernod.com/news/harrow-partners-with-healthcare-market-access-technology-platforms-to-support-launch-of-vevye/2482037/Harrow announced that it has partnered with three healthcare technology platforms to expand US availability of dry eye drug Vevye (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, twice-daily (BID) ophthalmic solution based on a water-free semifluorinated alkane (
- Sight Sciences Announces Withdrawal of Final LCDs on MIGS from Five Medicare Administrative Contractorshttps://modernod.com/news/sight-sciences-announces-withdrawal-of-final-lcds-on-micro-invasive-glaucoma-surgery-from-five-medicare-administrative-contractors/2482031/In a major decision that could a have wide-reaching effect on the future of reimbursement and access to care for glaucoma patients, five Medicare Administrative Contractors (MACs) decided to withdraw their final local coverage determinations (LCDs) for certain Micro-Invasive Glaucoma Su
- Visiox Pharmaceuticals to be Listed on Nasdaq Through Combination with PowerUp Acquisitionhttps://modernod.com/news/visiox-pharmaceuticals-to-be-listed-on-nasdaq-through-combination-with-powerup-acquisition/2482029/Visiox Pharmaceuticals and PowerUp Acquisition Corp. announced the execution of a definitive agreement for a business combination that would result in Visiox becoming a publicly traded company on the Nasdaq Capital Market. The business combination is expected to close in the first quarter of
- iSTAR Medical Continues European Expansion with First MINIject Surgeries in the Netherlandshttps://modernod.com/news/istar-medical-continues-european-expansion-with-first-miniject-surgeries-in-the-netherlands/2482027/iSTAR Medical announced the successful first implantations of MINIject, the company’s bio-integrating, minimally-invasive glaucoma surgery (MIGS) device, in the Netherlands. Patients were successfully implanted at the University Eye Clinic of the Maastricht University Medical Center+ b
- Nicox Announces First Patient Screened in the Whistler Phase 3b Trial of NCX 470 in Glaucomahttps://modernod.com/news/nicox-announces-first-patient-screened-in-the-whistler-phase-3b-trial-of-ncx-470-in-glaucoma/2482018/Nicox announced that the first patient has been screened in the Whistler phase 3b clinical trial investigating the dual mechanism of action (nitric oxide and prostaglandin analog) of NCX 470 in IOP lowering. NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop, is the company's le
- Azura Ophthalmics Announces Positive Results from Phase 2 Clinical Trial of AZR-MD-001 in Patients with Contact Lens Discomforthttps://modernod.com/news/azura-ophthalmics-announces-positive-results-from-phase-2-clinical-trial-of-azr-md-001-in-patients-with-contact-lens-discomfort/2482017/Azura Ophthalmics announced positive topline efficacy and safety results from a phase 2 study of AZR-MD-001 in patients with Contact Lens Discomfort (CLD) who could not comfortably wear their lenses as desired and who demonstrated signs of meibomian gland dysfunction (MGD). The trial met its prim
- Carl Zeiss Meditec to Acquire Dutch Ophthalmic Research Center (DORC)https://modernod.com/news/carl-zeiss-meditec-to-acquire-dutch-ophthalmic-research-center-dorc/2482014/In a move to expand its position in the vitreo-retinal surgery segment and strengthen its position in the ophthalmic medical device category globally, Carl Zeiss Meditec announced it has entered into an agreement to acquire 100% of the shares in Dutch Ophthalmic Research Cente
- Clearside Biomedical Completes Randomization in Phase 2b Clinical Trial of CLS-AX in Wet AMDhttps://modernod.com/news/clearside-biomedical-completes-randomization-in-phase-2b-clinical-trial-of-cls-ax-in-wet-amd/2482013/Clearside Biomedical announced it has completed randomization in its ODYSSEY Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) in wet age-related macular degeneration (AMD). Topline data results are expected in the third quarter of 2024. “As we continue
- Ocugen Announces First Patient Dosed in Phase 1/2 Trial of OCU410 Modifier Gene Therapy for GAhttps://modernod.com/news/ocugen-announces-first-patient-dosed-in-phase-12-trial-of-ocu410-modifier-gene-therapy-for-ga/2482006/Ocugen announced that the first patient has been dosed in the ArMaDa phase 1/2 clinical trial of OCU410 (AAV-RORA), a modifier gene therapy product candidate being developed for dry AMD (AMD). This phase 1/2 trial will assess the safety and efficacy of OCU410 for geographic at